El abordaje multidisciplinar del pie diabético permite reducir el número de amputaciones de extremidades inferiores • Éste es el propósito de un estudio desarrollado por el Hospital Torrecárdenas de Almería, primer centro hospitalario andaluz en implantar una consulta multidisciplinar, en la que trabajan de forma conjunta cirujanos vasculares y endocrinólogos
The global sales of drug-eluting balloons across the 10 major markets are expected to witness a significant increase over the coming years, from US$164m in 2012 to US$477m in 2019, at a Compound Annual Growth Rate of 16%, following the product’s launch in the USA and Japanese markets, according to a new report from GlobalData.
Biotronik (Lake Oswego, OR) announced the results from two independent clinical studies concerning the company’s Pulsar-18 self-expanding stent system in the treatment of superficial femoral artery (SFA) disease. The prospective, multicenter 4EVER study’s 24-month results were backed up by 12-month results from the multicenter, prospective PEACE registry. In both studies, the Pulsar stent’s efficacy data compared favorably with study results for other bare-metal stents, stated the company.
In the International Society of Endovascular Specialists’ Journal of Endovascular Therapy, Mario Lachat, MD, et al published midterm results showing a high success rate using the chimney stent graft technique and its periscope variation to treat patients with complex aortic aneurysms (2013;20:597–605).
Researchers from Universite Laval’s Faculty of Medicine and CHU de Quebec have shown that it is possible to treat venous ulcers unresponsive to conventional treatment with wound dressings made from human skin grown in vitro. A study published in the journal Advances in Skin and Wound Care demonstrates how this approach was successfully used to treat venous lower-extremity ulcers in patients who had been chronically suffering from such wounds.
A UK national initiative to carry out mandatory screening of hospital patients for deep vein thrombosis has resulted in a “significant” reduction in death rates, experts in Birmingham have concluded. A major study was carried out involving every single patient admitted to all 163 National Health Service (NHS) hospital trusts in England between July 2010 and March 2012
AccessClosure announced on 8 October 2013 an exclusive agreement with Ostial Corporation to distribute the Flash Ostial System Dual Balloon Angioplasty Catheter in the United States. The Flash Ostial System is designed to help overcome the challenges of aorto-ostial stenting and compliments the Mynx Product Family of Vascular Closure Devices to expand AccessClosure’s portfolio.
Data presented during a late breaking clinical trials session at VIVA13 show that a stent with three dimensional helical geometry, BioMimics 3D (Veryan Medical), have demonstrated safety and promising clinical performance at 12 months in the treatment of patients with peripheral arterial disease undergoing femoropopliteal artery intervention.
LEVANT 2, the first clinical trial in the USA to study the use of drug-coated balloons (CR Bard’s Lutonix) for femoropopliteal artery disease, found the procedure is promising for safety and efficacy at six months.
November 6, 2013—Gore & Associates (Flagstaff, AZ) announced that the US Food and Drug Administration (FDA) has approved the 25-cm Gore Viabahn endoprosthesis with heparin bioactive surface for the treatment of symptomatic peripheral arterial disease lesions in the superficial femoral artery (SFA). The new, 25-cm endoprosthesis is designed to cover long-segment lesions in the SFA, potentially reducing the need for multiple devices.
Initial results from its ANCHOR post-market registry evaluating the use of the Heli-FX EndoAnchor System in endovascular aneurysm repair (EVAR) were presented at the VIVA conference in Las Vegas, USA, on 8 October 2013. In the first 250 patients treated with the device in the study, there was a high degree of technical success in both treatment arms—primary group and revision group.
On 31 October, Endologix announced that the first patient was enrolled in the global registry for the Nellix Endovascular Aneurysm Sealing system. The global registry, is one of a number of clinical studies that make up the broader EVAS Forward clinical programme aimed at establishing clinical and economic evidence for endovascular aneurysm sealing (EVAS
The first successful implantations have been carried out in Italy and the United Kingdom, providing endovascular repair to iliac arteries.
An endovascular aortic repair (EVAR) revolution may be here, Andrew Holden, associate professor of Radiology, Auckland City Hospital, Auckland, New Zealand, told delegates at the CIRSE annual meeting (14–18 September, Barcelona, Spain)
David Safley presented the three-year health related quality of life data from the STROLL clinical trial during a late-breaking clinical trials session at the Vascular Interventional Advances (VIVA) 2013 Annual Meeting in Las Vegas, USA.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos